Evidence map›Paper›PMID 36464876›Full record

ArticleCurrent drug metabolism2022

Pharmacokinetics and Tissue Distribution of Nasal Spray of a Novel Muscarinic Receptor Blocker, 101BHG-D01, in Dogs and Rats.

Hao Wei, Lei Wu, Yongliang Jia, Jian Shen, Yanyou Li, Peng Sun, Qiangmin Xie, Xiaoping Chen, Yicheng Xie, Yingshuo Wang and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current drug metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Hao WeiDepartment of Pharmacy, Xuzhou Medical University, Xuzhou, 221004, China.
Lei WuDepartment of Pulmonology, The Children's Hospital, National Clinical Research Center For Child Health, Zhejiang University School of Medicine, Hangzhou, 310052, China.
Yongliang JiaKey Laboratory of Respiratory Drugs Research, Zhejiang University School of Medicine, Hangzhou, 310058, China.
Jian ShenKey Laboratory of Respiratory Drugs Research, Zhejiang University School of Medicine, Hangzhou, 310058, China.
Yanyou LiBeijing Showby Pharmaceutical Co., LTD, Beijing, China.
Peng SunInnovation Research Institute of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China.
Qiangmin XieKey Laboratory of Respiratory Drugs Research, Zhejiang University School of Medicine, Hangzhou, 310058, China.
Xiaoping ChenBeijing Showby Pharmaceutical Co., LTD, Beijing, China.
Yicheng XieDepartment of Pulmonology, The Children's Hospital, National Clinical Research Center For Child Health, Zhejiang University School of Medicine, Hangzhou, 310052, China.
Yingshuo WangDepartment of Pulmonology, The Children's Hospital, National Clinical Research Center For Child Health, Zhejiang University School of Medicine, Hangzhou, 310052, China.
Ziming ZhaoDepartment of Pharmacy, Xuzhou Medical University, Xuzhou, 221004, China.
Children's Hospital of Zhejiang University · CNZhejiang University · CNXuzhou Medical College · CNShandong University of Traditional Chinese Medicine · CN

Funding

National Key R&D Program of China 2019YFE0126200National Natural Science Foundation of China 82173819, 62076218, 81773643Zhejiang Province Public Welfare Technology Application Research Project LGF22H010002
6 · The paper itself

Abstract

background101BHG-D01 is a novel selective anti-muscarinic (M) 3 receptor-blocking drug. 101BHGD01 nasal spray is intended to be used to relieve sneezing and runny nose symptoms caused by allergic rhinitis.

methodsIn this study, we examined the plasma pharmacokinetics, tissue distribution, and major excretion mode of 101BHG-D01 in Beagle dogs and rats following nasal spray and intranasal administration, respectively, using HPLCMS/ MS. RESULTS/DISCUSSION: We found that the pharmacokinetics of 101BHG-D01 was linear in dogs. 101BHG-D01 entered the bloodstream rapidly following nasal spray. Its plasma half-life was approximately 6 h and resided at least 24 h in the body. Moreover, 101BHG-D01 retained a significant amount in the nasal cavity. Finally, we found that 101BHGD01 was eliminated mainly in the form of stools in rats.

conclusionIn conclusion, we provided pertinent reference information regarding the design and optimization of drug delivery regimens for clinical trials.

Indexed as

cholinergic receptorsM3 receptor blockernasal sprayParkinson's disease.pharmacokineticstissue distribution

Identifiers

PMID36464876
PMCPMC10186379
OpenAlexW4310671727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.